Pfizer Inc. said it launched a study of its oral Covid-19 treatment among children age 6 and up who have been infected by the virus and are at risk of progressing to severe disease.
The New York-based drugmaker said in a statement on Wednesday that it will enroll 140 children age 6 to 17 in the late-stage trial of its COVID-19 pill, Paxlovid. Pfizer seeks to eventually include even younger children in the safety and efficacy study.
“There is a significant unmet need for outpatient treatments that can be taken by children and adolescents to help prevent progression to severe illness, including hospitalization or death,” Chief Scientific Officer Mikael Dolsten said in a statement.
